CVRx, Inc. (CVRX)

US — Healthcare Sector
Peers: OSA  LIVN  ELMD  KIDS  SRDX  LUNG  HSKA  OFIX  NPCE  AORT  SGHT  AXDX  ANIK  AXGN 

Automate Your Wheel Strategy on CVRX

With Tiblio's Option Bot, you can configure your own wheel strategy including CVRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CVRX
  • Rev/Share 2.0432
  • Book/Share 2.6805
  • PB 2.5369
  • Debt/Equity 0.7228
  • CurrentRatio 14.8253
  • ROIC -0.4189

 

  • MktCap 177293680.0
  • FreeCF/Share -1.6066
  • PFCF -4.2646
  • PE -3.4137
  • Debt/Assets 0.3869
  • DivYield 0
  • ROE -0.7904

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade CVRX JP Morgan Neutral Underweight -- $7 May 9, 2025
Upgrade CVRX William Blair Market Perform Outperform -- -- Jan. 14, 2025
Initiation CVRX Cantor Fitzgerald -- Overweight -- $14 Sept. 10, 2024

News

CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CVRX
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative

CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
CVRX
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction

Read More
image for news CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

About CVRx, Inc. (CVRX)

  • IPO Date 2021-06-30
  • Website https://www.cvrx.com
  • Industry Medical - Devices
  • CEO Mr. Kevin Hykes
  • Employees 206
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.